Business Wire

MRM Health Completes Patient Recruitment in Ulcerative Colitis Study, Secures Financing and Provides Outlook for 2023


MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics based on its proprietary and unique CORAL® platform technology - today provided a business update on its different ongoing therapeutic programs and an outlook for 2023.

Key anticipated milestones for 2023:

- Top-line data from Phase 2a trial with MH002 in Ulcerative Colitis in Q3 2023 and mechanistic readouts in Q4 2023
- Initial data from open label Phase 2 trial with MH002 in Acute Pouchitis in Q4 2023
- Preclinical proof-of-concept in Type 2 Diabetes program partnered with IFF
- Completion of in vivo disease model studies in Parkinson’s Disease program

In 2022, we delivered not only on key milestones regarding the progress of our clinical programs, but also on key preclinical targets and we obtained additional dilutive and non-dilutive financing to continue our ambitious growth plans,” said Sam Possemiers, Chief Executive Officer of MRM Health. “2023 also started very promising as we reached a major milestone by completing early January patient recruitment in the Phase 2a study with MH002 in Ulcerative Colitis, while patient recruitment in our phase 2 study in Acute Pouchitis continues to progress. Leveraging on the power of our CORAL® platform and building further on the successes from 2022, our preclinical programs in Type 2 Diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and Parkinson’s Disease will further advance, with preclinical proof-of-concept expected in 2023 for the T2D program. Our effective progress provided confidence to SFPIM to join MRM Health and to partner with our existing investors to close a follow-on financing to continue on our path to success.”

Clinical Development with MH002 in Ulcerative Colitis and acute Pouchitis

MRM Health’s MH002-UC-201 study is a multi-center, double-blind, randomized, placebo-controlled trial with clinical sites in Belgium, Poland and Czech Republic, designed to evaluate safety, mechanistic effects, and initial efficacy of MH002 on disease activity. MRM Health has now enrolled all 45 mild-to-moderate UC patients. More information about the trial is available at

Dr. Ludo Haazen, Chief Medical Officer at MRM Health commented: “We are very pleased to have completed the recruitment for this ground-breaking UC trial, which is a true milestone for MRM Health and the development of our lead product MH002. We now look forward to analysing the clinical outcome data during 2023.”

MH002 is currently the most advanced rationally-designed consortium therapy in the UC field. Developed through MRM Health’s proprietary CORAL® Technology, MH002 consists of 6 well-characterized commensal strains, selected and optimized to tackle key disease-driving mechanisms with enhanced potency, resiliency, and engraftment. MH002 is produced using MRM Health’s breakthrough scalable and standardized cGMP manufacturing platform, allowing the manufacturing of complete consortia as a single drug substance, expected to provide both key regulatory and patient compliance advantages.

In addition, MH002 is currently also being investigated in an ongoing multi-center, open label Phase 2 study enrolling patients with Acute Pouchitis, a rare disease with high unmet medical need.

Partnered program with IFF in Metabolic Diseases

MRM Health has an ongoing corporate partnership with IFF since 2020, aiming to tackle a range of metabolic diseases. In this research, the proprietary CORAL® platform and selected IFF strains are combined to develop novel therapeutics based on live bacterial strain combinations. As part of its ongoing program in T2D, MRM Health recently reached a next milestone upon successfully achieving preclinical development targets. Within the ongoing program in NAFLD, MRM Health and IFF continue to further build on promising lead consortia and preclinical results, showing that a nine-strain bacterial consortium delays NAFLD progression and liver fibrosis. Part of this work was recently published in Biomedicines.

Preclinical programs

MRM Health has an ongoing preclinical program in Parkinson’s Disease (PD), in which it leverages on its proprietary CORAL® technology for the accelerated development of therapeutic consortia targeting neuroinflammation and neuronal cell death, two hallmarks of PD. Based on recent findings on specific microbiome signatures in PD, obtained from extensive in-house PD patient cohort analysis, and in vivo disease model data showing the capacity of specific bacterial strains to impact the target disease mechanisms, MRM Health was recently awarded a 2M EUR subsidy grant from the Flemish subsidy agency VLAIO. This will further accelerate the Company’s R&D activities in the field of PD and allow to progress a novel and differentiating therapeutic strategy to the clinic.

MRM Health further has an ongoing discovery program in the field of Spondyloarthritis (SpA), leveraging on its partnership with VIB and the leading expertise of prof. Jeroen Raes (VIB – KU Leuven) and prof. Dirk Elewaut (VIB – UGent). In-depth analysis of microbiome shifts in SpA patients revealed specific and actionable microbiome signatures in SpA. A rationally designed therapeutic consortium candidate was recently tested in the TNFdeltaARE mouse model, showing significant protection from disease development.

Intellectual Property

MRM Health’s IP position in the microbiome field was significantly strengthened, when the US Patent Office recently issued 3 novel US Patents, covering a broad range of consortia therapeutics and therapeutic methods for reducing gastrointestinal diseases. Novel applications were filed in the last 12 months on both MRM Health’s therapeutic consortia and aspects of the proprietary CORAL® platform while additional patents are expected to be granted in 2023.

About CORAL®

MRM Health’s CORAL® platform utilizes a bioinformatics-guided in-human discovery engine, combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows for the development of next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity and increased robustness.

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in two Phase 2 studies in patients with mild-to-moderate Ulcerative Colitis and acute Pouchitis, respectively. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis.

To view this piece of content from, please give your consent at the top of this page.

Contact information

For further information please contact:

Dr Sam Possemiers – CEO
Christiane Verhaegen – CFO
Phone: +

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SimCorp Unites with FlexTrade to Add New EMS Ecosystem Partner28.3.2023 09:02:00 CEST | Press release

SimCorp, an independent provider of investment management solutions, has partnered with FlexTrade Systems, a global leader in high-performance multi-asset trade execution management systems (EMS), to extend SimCorp's Order Management System (OMS) capabilities by incorporating the cross-asset EMS functionality of FlexTrade's FlexTRADER EMS. This partnership addresses the increasing demand from trading teams for seamless integration and collaborative workflows between their OMS and EMS solutions. The integration will help optimize trading activities and assist in meeting best execution obligations. As part of the partnership, FlexTrade will join SimCorp's Open Platform program. The Open Platform program is designed to offer its client base frictionless access to innovative fintech solutions across the investment value chain. A key component of the new agreement will see the two firms work together to deliver enhanced, seamless connectivity between SimCorp's OMS, Order Manager, and FlexTr

euNetworks Forms Exclusive Partnership on CrossChannel Fibre System to Deliver Ultra-Low Latency Services Between London and Madrid28.3.2023 09:00:00 CEST | Press release

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has entered into an exclusive partnership agreement with Crosslake Fibre UK Limited (“Crosslake”), an international network provider and developer of unique subsea and terrestrial fibre networks. This partnership relates to Crosslake’s new CrossChannel Fibre system and gives euNetworks exclusivity to deliver ultra-low latency services between the United Kingdom and Madrid on this system to the financial services community. euNetworks has also agreed to a strategic relationship, enabling the sale of dark fibre services by euNetworks using the system. This press release features multimedia. View the full release here: Paula Cogan, CEO of euNetworks (Photo: Business Wire) CrossChannel Fibre is a 550km cable system with end-to-end fibre running between Slough, United Kingdom and Paris, France and is the first subsea

Adva Network Security protects TransnetBW’s communication network28.3.2023 09:00:00 CEST | Press release

Adva Network Security today announced that TransnetBW has deployed its ConnectGuard™ encryption technology with the Adtran FSP 3000 optical transport solution to establish a highly secure communication network in its service area. As the operator of an electricity transmission grid in southwestern Germany and a European interconnection partner, TransnetBW depends on the security and reliability of its communication network to ensure trouble-free operations. That’s why the company chose the FSP 3000 optical platform with Adva Network Security encryption technology, which has been approved by the German Federal Office for Information Security (BSI). This solution enables high-speed connections to be reliably and robustly protected, even against sophisticated cyberattacks. Planning and implementation of the highly secure infrastructure were carried out by Adva Network Security’s long-standing partner Syserso Networks, who will also provide ongoing support. This press release features mult

Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse ® G NfL CSF and Lumipulse ® G NfL Blood tests28.3.2023 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes. The two assays are available for Research Use Only. “In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative

Sofinnova Partners Launches Digital Medicine Strategy28.3.2023 06:00:00 CEST | Press release

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today that it has launched a new investment strategy focused on digital medicine. The strategy will be headed by Partners Edward Kliphuis and Simon Turner, who bring over a decade of experience investing in startups at the intersection of biology, data, and computation. This press release features multimedia. View the full release here: Edward Kliphuis (left) and Simon Turner (right) (Photo: Business Wire) Sofinnova Digital Medicine will back entrepreneurs innovating at the cutting edge of technology and biology and help them scale to become global leaders. Like all the funds on Sofinnova’s platform, Sofinnova Digital Medicine will focus on developing the most promising innovations that address systemic challenges in healthcare and can profoundly improve the lives of patients worldwide. Antoine Pap